2018 年第三季度报告 2.1 主要财务数据 公司代码：600993 公司简称：马应龙 马应龙药业集团股份有限公司 2018 年第三季度报告 1 / 24 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 10 | 2018 年第三季度报告 一、 重要提示 二、 公司基本情况 | 单位：元 币种：人民币 | | --- | | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | --- | | | | | | 减(%) | | | 总资产 | 2,847,770,738.75 | 2,753,954,807.23 | | | 3.41 | | 归属于上市公司 | 2,216,065,275.75 | 2,192,172,943.96 | | | 1.09 | | 股东的净资产 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | | 比上年同期增减( ...

1 / 139 2018 年半年度报告 重要提示 2018 年半年度报告 公司代码：600993 公司简称：马应龙 马应龙药业集团股份有限公司 2018 年半年度报告 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人陈平、总经理苏光祥、主管会计工作负责人陈玲莉及会计机构负责人（会计主管 人员）汪丽红声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 第二节 公司简介和主要财务指标 否 九、 重大风险提示 本报告"经营情况的讨论与分析"一节中已经详细描述公司可能面对的风险，敬请投资者关 注并注意投资风险 ...

Financial Performance - The company achieved a net profit of CNY 340,417,985.73 in 2017, with an increase in retained earnings to CNY 1,383,659,317.34 after distributing CNY 99,142,394.93 in cash dividends [5]. - Total revenue for 2017 was CNY 1,750,592,393.66, representing a decrease of 16.75% compared to CNY 2,102,806,895.51 in 2016 [21]. - The net profit attributable to shareholders increased by 27.90% to CNY 320,051,428.15 from CNY 250,243,913.86 in the previous year [21]. - The company reported a basic earnings per share of CNY 0.74, up 27.59% from CNY 0.58 in 2016 [22]. - Cash flow from operating activities increased by 48.65% to CNY 356,168,369.00 compared to CNY 239,599,870.10 in 2016 [21]. - The company achieved operating revenue of CNY 1.75 billion, a decrease of 16.75% compared to the previous year [47]. - Net profit attributable to shareholders reached CNY 320 million, an increase of 27.9% year-on-year [47]. - The gross profit margin decreased to 49.77%, down from the previous year, reflecting a decline of 34.82% in operating costs [52]. Assets and Investments - The total assets of the company rose to CNY 2,753,954,807.23, marking a 10.30% increase from CNY 2,496,726,679.77 in 2016 [21]. - The company’s fair value measurement of financial assets increased from 21,166,100.00 RMB at the beginning of the period to 208,000,000.00 RMB at the end, reflecting a change of 186,833,900.00 RMB [29]. - The total assets of the company rose from 28,503,969.80 RMB to 215,344,874.02 RMB, indicating a substantial increase of 186,840,904.22 RMB [30]. - The company’s cash and cash equivalents increased by 70.03% to 932,330,377.27 yuan, representing 33.85% of total assets [68]. Market and Industry Position - The company operates in the pharmaceutical manufacturing industry, focusing on the production of over 300 types of traditional Chinese medicine and more than 20 exclusive products [32]. - The company maintained a market share of 49.6% in the domestic retail terminal hemorrhoid medication market, solidifying its leading position [37]. - The domestic market for hemorrhoid medication reached CNY 3.1 billion in 2017, with a year-on-year growth of 7.6% [76]. - The retail market for hemorrhoid medication totaled CNY 1.78 billion, growing by 5.9% year-on-year, while the hospital terminal market reached CNY 1.33 billion, growing by 10% [76]. Research and Development - Research and development expenditures amounted to CNY 41.27 million, an increase of 11.81% from the previous year [49]. - The company invested a total of 4,126.6 million RMB in R&D during the reporting period, representing an increase of 11.8% compared to the previous year, with R&D expenses accounting for 3.67% of the company's pharmaceutical industrial revenue [90]. - The company is currently conducting clinical research on several key projects, including the second-generation Ma Yinglong musk hemorrhoid ointment and the sulfonated testosterone sodium tablets [93]. - The company has completed process validation for several products, including the nitroglycerin ointment and mesalazine enteric-coated tablets, which are now in the preclinical research phase [91]. Strategic Plans and Future Outlook - The company plans to distribute a cash dividend of CNY 2.3 per 10 shares, totaling CNY 99,142,394.93 [5]. - The company aims to enhance its procurement and production processes to reduce costs and improve inventory turnover rates [32]. - The company plans to expand its market presence and invest in new product development to counteract declining revenues in certain regions [52]. - The company aims to transform into a "provider of comprehensive anal health solutions," focusing on offering a full range of diagnostic, pharmaceutical, and medical device services [95]. Corporate Governance and Management - The total pre-tax compensation for the chairman Chen Ping is 0.0 million yuan, while the total for the general manager Su Guangxiang is 138.8 million yuan [176]. - The company continues to maintain a stable leadership structure with no changes in the board of directors and senior management during the reporting period [176]. - The company has established a dual-track salary system for management and operational staff, ensuring compensation aligns with job value and contribution [187]. - The company has a diverse board with members holding various academic and professional qualifications, enhancing its governance and strategic decision-making capabilities [178]. Environmental Compliance - The company has complied with environmental protection laws and regulations, demonstrating significant environmental performance [153]. - In 2017, the main pollutant discharge monitoring values of Beijing Changqing Hospital were all below the standard limits, with no environmental pollution disputes or incidents occurring throughout the year [152]. - The hospital's pollution prevention facilities are fully constructed, regularly maintained, and operate normally, ensuring that pollutant discharge concentrations meet the required limits [153].

2018 年第一季度报告 公司代码：600993 公司简称：马应龙 马应龙药业集团股份有限公司 2018 年第一季度报告 1 / 22 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2018 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 未出席董事情况 | 未出席董事姓名 | 未出席董事职务 | 未出席原因的说明 | 被委托人姓名 | | --- | --- | --- | --- | | 马健驹 | 董事 | 工作原因 | 游仕旭 | 1.3 公司负责人陈平、总经理苏光祥、主管会计工作负责人陈玲莉及会计机构负责人（会计主管 人员）汪丽红保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | | ...

2017 年第三季度报告 公司代码：600993 公司简称：马应龙 马应龙药业集团股份有限公司 2017 年第三季度报告 1 / 24 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 10 | | 目录 | | --- | 一、 重要提示 单位：元币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 2,630,338,894.91 2,496,726,679.77 5.35 归属于上市公司 股东的净资产 2,112,071,434.30 1,940,275,907.46 8.85 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的 现金流量净额 242,573,918.61 168,359,221.68 44.08 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （%） 营业收入 1,190,881,244.51 1,410,011,913.16 -15.54 归属 ...

2017 年半年度报告 公司代码：600993 公司简称：马应龙 马应龙药业集团股份有限公司 2017 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 四、 公司负责人陈平、总经理苏光祥、主管会计工作负责人陈玲莉及会计机构负责人（会计主管 人员）汪丽红声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无。 六、 前瞻性陈述的风险声明 √适用□不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 否 九、 重大风险提示 本报告"经营情况的讨论与分析"一节中已经详细描述公司可能面对的风险，敬请投资者关 注并注意投资风险。 1 / 140 2017 年半年度报告 十、 其他 □适用 √不适用 ...

马应龙药业集团股份有限公司 2016 年年度报告 2016 年年度报告 重要提示 四、 公司负责人陈平、总经理苏光祥、主管会计工作负责人陈玲莉及会计机构负责人（会计主管 人员）汪丽红声明：保证年度报告中财务报告的真实、准确、完整。 公司代码：600993 公司简称：马应龙 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经中审众环会计师事务所（特殊普通合伙）审计，公司 2016 年度实现净利润 264,354,938.11 元（为母公司数，下皆为母公司数），加上 2016 年初公司未分配利润 977,743,443.71 元，减去 发放的 2015 年度现金股利 86,210,778.20 元、提取法定盈余公积 26,435,493.81 元、2016 年末 公司可供股东分配的利润为 1,129,452,109.81 元。 第九届董事会第五次会议审议通过公司 2016 年度利润分配预案如下： 以2016年年末总股本431,053,891股为基数，向全体股东每10股派发现金股利2元（含税）， 派发现金股利总额为86,210,778.20元。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的 ...

Financial Performance - Operating revenue for the period was CNY 385,812,281.73, representing a decline of 18.91% year-on-year[7] - Net profit attributable to shareholders was CNY 86,696,427.09, an increase of 8.03% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was CNY 80,296,218.30, an increase of 13.18% year-on-year[7] - Total operating revenue for Q1 2017 was CNY 385,812,281.73, a decrease of 19% from CNY 475,801,703.32 in the previous period[29] - Net profit for Q1 2017 reached CNY 85,677,075.21, an increase of 10% compared to CNY 78,003,783.72 in the same period last year[29] - The net profit attributable to shareholders of the parent company was CNY 86,696,427.09, up from CNY 80,253,028.33, reflecting a growth of 8%[29] - The company's operating revenue for the current period reached ¥244,785,360.87, an increase of 16.6% compared to ¥209,994,986.54 in the previous period[33] - The net profit for the current period was ¥90,722,956.91, reflecting a growth of 14.1% from ¥79,602,224.09 in the same period last year[33] - The total profit for the current period was ¥105,689,814.95, an increase of 14.9% from ¥92,021,988.51 in the previous period[33] Cash Flow - Net cash flow from operating activities reached CNY 56,871,232.09, a significant increase of 1,037.38% year-on-year[7] - Net cash flow from operating activities increased by 1037.38% to ¥56,871,232.09, mainly due to increased cash received from goods purchased and services rendered[15] - The net cash flow from operating activities was ¥56,871,232.09, significantly higher than ¥5,000,182.36 in the previous period[36] - The cash flow from investment activities showed a net inflow of ¥10,542,408.04, a recovery from a net outflow of ¥95,501,631.88 in the previous period[37] - The net increase in cash and cash equivalents for Q1 2017 was $64,416,558.45, compared to a decrease of $98,315,700.34 in the previous period[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,439,042,567.99, a decrease of 2.31% compared to the end of the previous year[7] - Total assets decreased to ¥2,439,042,567.99 from ¥2,496,726,679.77, indicating a decline in overall asset value[20] - Total liabilities decreased to ¥352,341,663.37 from ¥479,875,687.37, showing a significant reduction in financial obligations[20] - Total liabilities increased to CNY 239,290,850.24 from CNY 210,693,788.83, representing a rise of approximately 14%[24] - Current assets totaled CNY 1,337,876,963.85, up from CNY 1,213,879,005.23, indicating a growth of about 10%[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 39,357[10] - The largest shareholder, China Baoan Group Co., Ltd., held 29.27% of the shares, amounting to 126,163,313 shares[10] Earnings and Costs - Basic earnings per share were CNY 0.20, reflecting a growth of 5.26% compared to the previous year[7] - Operating costs decreased by 38.73% to ¥184,567,799.90 due to a reduction in the scope of consolidation[13] - Total operating costs for Q1 2017 were CNY 294,120,787.51, down 26% from CNY 396,309,214.31 in the previous period[29] - The operating profit increased to ¥103,514,525.51, up by 13.5% from ¥91,254,381.28 in the previous period[33] Other Financial Metrics - The weighted average return on equity rose to 4.37%, up by 0.20 percentage points from the previous year[7] - The company reported non-operating income of CNY 6,400,208.79 for the period[9] - Financial expenses decreased by 183.62% to -¥284,290.62 primarily due to reduced bank interest expenses[13] - Other receivables increased by 188.07% to ¥64,058,310.06, driven by growth in business-related deposits and guarantees[18] - Short-term borrowings decreased by 90.06% to ¥9,000,000.00, also due to a reduction in the scope of consolidation[19] - Deferred income tax assets decreased by 30.89% to ¥8,222,472.65, resulting from a decrease in deductible temporary differences[19] - Prepayments increased by 41.31% to ¥32,673,460.91, reflecting business settlement activities during the period[19] - The company's financial expenses showed a slight increase, with a cost of -¥925,289.82 compared to -¥722,848.06 in the previous period[33]

2016 年第三季度报告 马应龙药业集团股份有限公司 2016 年第三季度报告 1 / 23 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2016 年第三季度报告 公司代码：600993 公司简称：马应龙 一、 重要提示 2.1 主要财务数据 单位：元币种：人民币 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | --- | | | | | 减(%) | | | | 总资产 | 2,541,024,381.34 | 2,409,866,798.30 | | | 5.44 | | 归属于上市公司 | 1,904,112,206.86 | 1,784,102,291.44 | | | 6.73 | | 股东的净资产 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | | | （1-9 月 ...

2016 年半年度报告 公司代码：600993 公司简称：马应龙 马应龙药业集团股份有限公司 2016 年半年度报告 重要提示 无。 六、 前瞻性陈述的风险声明 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 常用词语释义 | | | 日至 | 月 | 30 | 日 | | --- | --- | --- | --- | --- | --- | | | | 2016 | | | | | 马应龙、公司、本公司 报告期 | 指 指 | 马应龙药业集团股份有限公司 2016 年 1 月 1 年 6 | | | | 否 1 / 132 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人陈平、总经理苏光祥、主管会计工作负责人陈玲莉及会计机构负责人（会计主管 人员）汪丽 ...